“A personalized mRNA cancer vaccine for people with high-risk melanoma has succeeded in a large Phase 3 trial. The treatment, developed by Moderna and Merck, is individually designed from mutations found in each patient’s tumor and trains the immune system to recognize and attack their cancer. The companies have not yet released the full results from the Phase 3 trial. But in earlier Phase 2 results, the vaccine—combined with the immunotherapy drug Keytruda—reduced the risk of recurrence or death by 49 percent over five years versus Keytruda alone,” reports The Doomslayer.
The New York Times reports:
Read Full Article: https://libertyunyielding.com/2026/09/01/mrna-cancer-vaccine-succeeds-for-people-with-high-risk-melanoma/
